Ken Griffin Immix Biopharma, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Immix Biopharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 8,900 shares of IMMX stock, worth $17,533. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,900Holding current value
$17,533% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding IMMX
# of Institutions
30Shares Held
4.53MCall Options Held
8.9KPut Options Held
1.2K-
Aigh Capital Management LLC Baltimore, MD1.12MShares$2.21 Million0.68% of portfolio
-
Bleichroeder LP New York, NY850KShares$1.67 Million0.43% of portfolio
-
Cable Car Capital LLC San Francisco, CA796KShares$1.57 Million1.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA699KShares$1.38 Million0.0% of portfolio
-
Lynwood Capital Management Inc.405KShares$797,85011.13% of portfolio
About Immix Biopharma, Inc.
- Ticker IMMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,910,100
- Market Cap $27.4M
- Description
- Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specif...